Profile of candidiasis in HIV infected patients

Iranian Journal of Microbiology

Volumn 4, Issue 4, 2012, Pages 204-209

  Anwar Khan, P ^a   Malik, A ^a   Subhan Khan, H ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

AIDS; Candida; CD4 count; HIV

Indexed keywords

EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VORICONAZOLE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; FEMALE; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

CANDIDA; CANDIDA ALBICANS;

EID: 84869024746     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of the virus in plasma. Science 1996; 272: 1167-1170.
2. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C. et al. Randomisedplacebocontrolled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease RitonavirStudy Group. Lancet 1998; 351(9102): 543-549.
3. Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, Breux JP, Souala F, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12: 1815-1822
4. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005; 7: 429-439.
5. Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998; 12(4): 447-8.
6. Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12(18): 2511-3.
7. U.S. Public Health Service, Infectious Diseases Society of American Guidelines for preventing opportunistic infections among HIV-infected persons-2002. MMWR Recomm Rep. 2002 Jun 14; 51(RR08).
8. Calderone RA. Candida and candidiasis. Washington, DC: ASM Press, 2001.
9. Armstrong, D. 1989. Problems in management of opportunistic fungaldiseases. Rev. Infect. Dis. 1l (Supp1. 7): S1591-S1599.
10. Barr CE. Oral diseases in HIV-1 infection. Dysphagia.1992; 7: 126-37.
11. Chander J. Candidiasis. Textbook of Medical Mycology, 2nd ed. New Delhi:Mehta Publishers; 2009. p. 266-90
12. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. Sep 12003; 37(5): 634-43.
13. M. Vajpayee, S. Kanswal, P. Seth, N. Wig. Spectrum of Opportunistic Infections and Profile of CD4+ Counts among AIDS Patients in North India Infection 2003; 31: 336-340.
14. Sharma SK, Aggarwal G, Seth P, Saha PK: Increasing HIV seropositivity among adult tuberculosis patients in Delhi. Indian J MedRes 2003, 117: 239-242.
15. Anupriyawadhwa, Ravinder Kaur, Satish Kumar Agarwal, Shyama Jain and PreenaBhalla: AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India; Journal of Medical Microbiology 2007; 56: 1101-1106.
16. B.C. Pruthvi, S. Vikram, S.K. Suman, B. Jayaprakash, N.R. Rau, Spectrum of Clinical Presentation and Opportunistic Infections in HIV: An Indian Scenario, 13th International Congress on Infectious Diseases, e484, 2006.
17. Nagalingeswaran K, Solomon S, Madhivanan P, Yepthomi T, Venkatesan C, Amalraj E et al. Correlation between plasma viral load and CD4+T cell count to opportunistic infections in persons with HIV in South India. Int Conf AIDS. 2000 Jul 9-14; 13.
18. Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci 2003; 57: 16-21.
19. Sanjeypandey, Shyam Sunder, H Hasan, Ravi Shankar, SP Singh. Clinical profile and opportunistic infections in HIV/AIDS patients attending SS hospital varanasi, Indian J PrevSoc Medicine, vol. 39 no. 1 & 2, 2008.
20. Mulla SA, Patel MG, Vaghela G, Motala N, Desai V, Shrivastava RK. A study of opportunistic infection in HIVseropositive patients. Indian J Community Med 2007; 32: 208-9
21. Ismail H. Sahand, Jose L. Maza, Elena Eraso, Miguel Montejo, Maria D. Moragues, Jose M. Aguirr et al. Evaluation of CHROM-Pal medium for the isolation and direct identification of Candida dubliniensis in primary cultures from the oral cavity. Journal of Medical Microbiology (2009), 58, 1437-1442
22. Coleman, DC et al.Candidiasis: The emergence of a novel species,Candida dubliniensis. AIDS. 1997; 11557-567.
23. CA Enwuru1, A Ogunledun, N Idika, NV Enwuru, F Ogbonna, M. Aniedobe et al. Fluconazole resistant opportunistic oropharyngeal candida and non-candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. African Health Sciences. 2008; 8 No 3.
24. Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates fromhuman immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997; 41(3): 617-623.
25. Vazquez JA, Arganoza MT, Boikov D, Yoon S, Sobel JD, Akins RA. Stable phenotypic resistance of Candidaspecies to amphotericin B conferred by pre-exposuretosub-inhibitory levels of azoles. J Clin Microbiol 1998; 36(9): 2690-2695.
26. Cartledge JD, Midgely J, Gazzard BG. Clinically significantazole cross-resistance in Candida isolates from HIVpositivepatients with oral candidosis. AIDS 1997; 11: 1839-1844.
27. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
28. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25: 843-6.